ClinicalTrials.gg
RecruitingNCT05728658Updated Sep 8, 2025

The Study of ICP-248 in Patients With Mature B-cell Malignancies

A Phase 1 interventional study of ICP-248 and ICP-248 in Hematological Malignancies, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 22 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-08.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
191
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 148 studies in Hematologic Neoplasms with a site in China — 75 open to participants now, 83 under way, 8 of them phase 3. Hematologic Neoplasms · China.

Planned enrollment
20th of 123
191 · median 56
Started
2023
with 19 others
Phase 1
57 of 148
30 open now
Primary completion
2025-08
later than 18 of 82 live
Registered
76th of 148
by date

Among the 148 studies in Hematologic Neoplasms with a site in China, this one is the 20th largest by planned enrollment of the 123 interventional ones that give a count, is one of 20 that started in 2023, is one of 57 in phase 1, reaches primary completion later than 18 of the 82 other live ones, and was the 76th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 421 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

75 of the 148 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:

70 more — sign in →

All 75 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 314 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 148 studies in Hematologic Neoplasms with a site in China, or all of them as a file.
02

Study summary

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination Therapy in Patients with Mature B-cell Malignancies.This study consists of two parts: Part 1 dose-finding period and Part 2 dose expansion period.

03

Conditions studied

  • Hematological Malignancies
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and ≤ 80 years.
  2. One of the following histopathologically and/or flow cytometry-confirmed diseases according to the 2016 World Health Organization (WHO) classification criteria for lymphohematopoietic neoplasms or meeting the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria: Histopathologically and/or flow cytometry-confirmed CLL/SLL; confirmed MCL; Pathologically confirmed B-NHL, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), and lymphoplasmacytic lymphoma (LPL).
  3. disease or refractory disease
  4. For subjects with B-NHL: Patients must have measurable diseasePatients with an (ECOG) performance status (PS) score of ≤ 2 and a of ≥ 6 months.
  5. Adequate hematologic function.
  6. Patients with basically normal coagulation function.
  7. Patients with adequate hepatic, renal, pulmonary and cardiac functions.
  8. CLL/SLL Patients with an absolute lymphocyte count ≥ 50 x 109/L and any lymph nodes ≥ 5 cm in the long diameter or CLL/SLL or B-NHL patients with any lymph nodes ≥ 10 cm in the long diameter will be enrolled in the study after weighing the risks and benefits with the sponsor's MM.
  9. Female patients of must have a negative blood pregnancy test within 7 days prior to the first dose of the product; patients of childbearing potential (males and females) must agree to use a reliable method (hormonal or barrier method or abstinence) with their partners from signing the ICF until 90 days after the last dose.The last ICP- 248 dose or within one month after the last dose of Orelabrutinib Or within 12 months after the last dose of Rituximab (whichever is longer).
  10. Subjects are able to communicate with the investigator well and to complete the study as specified in the study.
  11. Before the trial, the subjects shall understand the nature, significance, possible benefits, inconveniences and potential risks, as well as the study procedures of the trial in detail and voluntarily sign the written Form (ICF).
  12. Subjects with CLL/SLL must have an indication for treatment as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  1. Prior (other than the disease under study) within 2 years before study entryKnown
  2. Central nervous system involvement by lymphoma/leukemia
  3. Underlying medical conditions that, in the investigator's opinion, will render the administration of the product hazardous or obscure the interpretation of the safety or efficacy results.
  4. Prior stem cell transplant (unless ≥ 3 months after transplant); or prior chimeric cell therapy (unless ≥ 3 months after cell infusion).
  5. Received a BCL-2 inhibitor prior to initial use of the investigational drug and did not achieve disease remission or disease recurrence/progression on treatment; Disease recurrence/progression after stopping or ending BCL-2 inhibitor therapy is acceptable.
  6. A history of allogeneic stem cell transplantation.
  7. Anti-cancer therapy within 14 days prior to the first dose of the investigational product
  8. An interval of less than 5 half-lives from the last dose of a strong inhibitor or inducer (chemical agent, traditional Chinese medicine and dietary supplement) to the first dose of the investigational product, or a plan to use concurrently medications, dietary supplements or food (e.g., grapefruit or grapefruit juice) with strong CYP3A inhibitory or inductive effect during study participation.
  9. Patients who have undergone major organ surgery (excluding aspiration ) or significant trauma within 28 days prior to the first dose of the investigational product, or who require elective surgery during the trial.
  10. Patients who have received a within 28 days prior to the first dose of the investigational product (except for vaccination to prevent a major public health event).
  11. Presence of active infection that currently requires intravenous systemic anti-infective therapy.
  12. Patients with active or C virus infection.
  13. History of immunodeficiency, including a positive (HIV) antibody test.
  14. History of significant cardiovascular disease
  15. Patients with previous or concomitant central nervous system disordersHistory or current evidence of severe interstitial lung disease.
  16. ≥ Grade 2 toxicity due to prior anti-cancer therapy at enrollment (except for alopecia, ANC, and ). For ANC, hemoglobin and PLT, please follow the inclusion criteria.
  17. History of severe bleeding disorder
  18. Known alcohol or drug dependence.
  19. Presence of mental disorders or poor compliance.
  20. Female patients who are pregnant or lactating.
  21. Unable to swallow tablets or disease significantly affecting gastrointestinal function.
  22. to the active substance or of ICP-248 tablets or Orelabrutinib tablets (only applicable to subjects in cohort G/H/J/K).Severe allergic reaction or intolerance to murine monoclonal antibodies or murine products.

23 Invasive mantle cell lymphoma, such as mother cell subtypes, polymorphic subtypes, or Ki-67 proliferation index>50%, must be discussed with the sponsor's medical monitor regarding patient benefits and risks before being included in this study.

Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
191 participants (estimated)

Study arms

  • Experimental
    Dose-Escalation Cohort - R/R CLL/SLL and R/R MCL

    ICP-248 was divided into 6 dose groups, and each dose group was given progressively

    Drug: ICP-248

  • Experimental
    Dose-Expansion Cohort A/B/C/D/E/F (R/R CLL/SLL、R/R MCL、R/R B-NHL)

    Participants will receive ICP-248 daily with a weekly ramp-up schedule from Cycle 1 day 1.

    Drug: ICP-248

  • Experimental
    Dose-Expansion Cohort G(R/R MCL)

    Participants will receive ICP-248 daily with a ramp-up phase, and will receive Orelabrutinib 150 mg daily, until progressive disease (PD),intolerable toxicity,withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death,or end of study,whichever occurs first.

    Drug: ICP-248+Orelabrutinib

  • Experimental
    Dose-Expansion Cohort H(R/R MZL)

    Participants will receive ICP-248 daily with a weekly ramp-up schedule and Orelabrutinib 150 mg daily from Cycle 1 day 1, until progressive disease (PD),intolerable toxicity,withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death,or end of study,whichever occurs first.

    Drug: ICP-248+Orelabrutinib

  • Experimental
    Dose-Expansion Cohort I(R/R CLL/SLL)

    Participants will receive ICP-248 daily with a weekly ramp-up schedule from Cycle 1 day 1, and will receive 375 mg/m2 Rituximab on day 1 of each cycle from C1 to C6,or until progressive disease (PD),intolerable toxicity,withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death,or end of study,whichever occurs first.

    Drug: ICP-248 +Rituximab

  • Experimental
    Dose-Expansion Cohort J(R/R CLL/SLL)

    Participants will receive Orelabrutinib 150 mg daily from cycle 1 day 1, and will receive ICP-248 daily with a daily ramp-up schedule from Cycle 3 day 1, until progressive disease (PD),intolerable toxicity,withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death,or end of study,whichever occurs first.

    Drug: ICP-248+Orelabrutinib

  • Experimental
    Dose-Expansion Cohort K(MCL)

    Participants will receive Orelabrutinib 150 mg daily from cycle 1 day 1, and Rituximab 375 mg per square meter was infused intravenously on day 1 of each cycle from C1-6 and on day 1 of every two cycles from C7D1 onwards, and ICP-248 daily with a weekly ramp-up schedule from cycle 3 day 1. The treatment will continue up to a maximum of 24 cycles, or until progressive disease (PD),intolerable toxicity,withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death,or end of study,whichever occurs first.

    Drug: ICP-248+Orelabrutinib+Rituximab

Interventions

  • Eligible patients will receive ICP-248 orally as per the protocol, once daily for every 28 days as one treatment cycle (except for the food effect investigation phase), until progressive disease (PD), intolerable toxicity, withdrawal of consent, loss to follow-up, initiation of other anti-cancer therapy, death, or end of study, whichever occurs first.

  • Eligible patients will receive ICP-248 orally as specified in the treatment arm.

  • DrugICP-248+Orelabrutinib

    Drug pages: Mesutoclax · Orelabrutinib

    Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

  • DrugICP-248+Orelabrutinib

    Drug pages: Mesutoclax · Orelabrutinib

    Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

  • DrugICP-248 +Rituximab

    Drug pages: Mesutoclax · Rituximab

    Eligible patients will receive ICP-248 and Rituximab as specified in the treatment arm.

  • DrugICP-248+Orelabrutinib

    Drug pages: Mesutoclax · Orelabrutinib

    Eligible patients will receive ICP-248 and Orelabrutinib as specified in the treatment arm.

  • DrugICP-248+Orelabrutinib+Rituximab

    Drug pages: Mesutoclax · Orelabrutinib · Rituximab

    Eligible patients will receive ICP-248 and Orelabrutinib and Rituximab as specified in the treatment arm.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose and recommended Phase 2 dose

    To evaluate the safety and tolerability of ICP-248 monotherapy or combination with Orelabrutinib in the selected B-cell malignancies and to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ICP-248

    Time frame: 5 years

  2. To investigate the incidence, nature and severity of adverse events (AE) according to NCI-CTCAE V5.0 or iwCLL2018 evaluation criteria.

    Time frame: 5 years

  3. To evaluate the investigator-assessed overall response rate (ORR) of ICP-248 monotherapy or combination therapy at the recommended phase II dose (RP2D) .

    Time frame: 5 years

Secondary outcomes

  1. Pharmacokinetic (PK) profile - Area under curve (AUC0-t)

    To evaluate the AUC0-t after single administration of ICP-248 and steady state of ICP-248.

    Time frame: 5 years

  2. Pharmacokinetic (PK) profile - Maximum Concentration (Cmax)

    To evaluate the Cmax after single administration of ICP-248 and steady state of ICP-248.

    Time frame: 5 years

  3. Pharmacokinetic (PK) profile - Time to maximum concentration (Tmax)

    To evaluate the Tmax after single administration of ICP-248 and steady state of ICP-248.

    Time frame: 5 years

  4. Pharmacokinetic (PK) profile - Apparent clearance (CL/F)

    To evaluate the CL/F after single administration of ICP-248 and steady state of ICP-248.

    Time frame: 5 years

  5. Preliminary efficacy - Complete response rate (CRR)

    To evaluate the preliminary efficacy of ICP-248 monotherapy in the evaluated disease types as measured by investigator-assessed complete response rate (CRR).

    Time frame: 5 years

  6. Preliminary efficacy - Progression-free survival (PFS)

    To evaluate the preliminary efficacy of ICP-248 monotherapy in the evaluated disease types as measured by investigator-assessed progression-free survival (PFS).

    Time frame: 5 years

  7. Preliminary efficacy - Duration of response (DOR)

    To evaluate the preliminary efficacy of ICP-248 monotherapy in the evaluated disease types as measured by investigator-assessed duration of response (DOR).

    Time frame: 5 years

  8. Preliminary efficacy - Overall survival (OS)

    To evaluate the preliminary efficacy of ICP-248 monotherapy in the evaluated disease types as measured by investigator-assessed overall survival (OS).

    Time frame: 5 years

  9. AUC of ICP-248 under different feeding conditions

    To evaluate the AUC of ICP-248 under different feeding conditions.

    Time frame: 5 years

  10. Maximum Concentration (Cmax) of ICP-248 under different feeding conditions

    To evaluate the Cmax of ICP-248 under different feeding conditions.

    Time frame: 5 years

  11. Time to maximum concentration (Tmax) of ICP-248 under different feeding conditions

    To evaluate the Tmax of ICP-248 under different feeding conditions.

    Time frame: 5 years

07

Study locations

22 of 22 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Aug 2025, 29 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 29 months is below that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2023
First posted
Feb 15, 2023
StartActual
Mar 9, 2023
Primary completionEst.
Aug 30, 2025
CompletionEst.
Oct 30, 2026
Last update
Sep 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05728658
Responsible party
Sponsor
First posted
Feb 15, 2023
Start date
Mar 9, 2023
Primary completion
Aug 30, 2025 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Sep 8, 2025

Study contacts

Shuhua Yi
Contact
yishuhua@ihcams.ac.cn
15900265415

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mesutoclax · Orelabrutinib · Rituximab

Start the discussion